We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 23.50 | 1.38% | 1,728.50 | 6,275,082 | 16:35:24 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1,727.50 | 1,728.50 | 1,729.50 | 1,695.50 | 1,705.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.44 | 71.14B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:42:12 | O | 5 | 1,725.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/5/2024 | 15:00 | UK RNS | GSK PLC Total Voting Rights |
| 01/5/2024 | 08:50 | ALNC |  TOP NEWS: GSK expects momentum to continue after strong first quarter |
| 01/5/2024 | 07:00 | UK RNS | GSK PLC 1st Quarter Results |
| 24/4/2024 | 09:14 | ALNC | GSK's Jemperli with chemotherapy accepted for priority review by FDA |
| 24/4/2024 | 07:00 | UK RNS | GSK PLC US FDA accepts new indication filing for Jemperli |
| 19/4/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 17/4/2024 | 15:30 | UK RNS | GSK PLC Director/PDMR Shareholding |
| 17/4/2024 | 08:46 | ALNC | TOP NEWS: GSK hails data on Shingles vaccine and gonorrhoea treatment |
| 17/4/2024 | 07:05 | UK RNS | GSK PLC GSK announces additional EAGLE-1 results |
| 17/4/2024 | 07:00 | UK RNS | GSK PLC Results from long-term data relating to Shingrix |
Gsk (GSK) Share Charts1 Year Gsk Chart |
|
1 Month Gsk Chart |
Intraday Gsk Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/5/2024 | 16:44 | Glaxosmithkline - The recovery | 32,923 |
| 01/2/2024 | 10:22 | GlazoSmithKline - News & Information | 142 |
| 24/9/2023 | 21:42 | GLAXOSMITHKLINE WITH CHARTS & NEWS | 188 |
| 17/4/2023 | 19:25 | Gsk zantac | 1 |
| 28/2/2023 | 16:35 | GSK launched Shingrix, which has a far superior shingles prevention effect | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:09:20 | 1,725.50 | 5 | 86.28 | O |
| 16:09:20 | 1,725.50 | 5 | 86.28 | O |
| 16:06:30 | 1,725.50 | 4 | 69.02 | O |
| 16:06:29 | 1,725.50 | 47 | 810.99 | O |
| 15:53:43 | 1,729.00 | 1 | 17.29 | O |
| Top Posts |
|---|
Posted at 02/5/2024 09:20 by Gsk Daily Update Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,705p.Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £71,142,337,809. Gsk has a price to earnings ratio (PE ratio) of 14.44. This morning GSK shares opened at 1,705p |
Posted at 02/5/2024 09:24 by geckotheglorious II view”GSK extends share price rally after very healthy results The turnaround at this UK pharmaceutical giant continues following these well-received quarterly results. City writer Graeme Evans explains why investors keep chasing the shares higher. Upgraded guidance and a bigger-than-expected quarterly dividend today moved GSK The drugs giant plans to pay shareholders 15p a share on 11 July, which US bank Jefferies said compared with the City consensus of 14.7p and its own 14.5p estimate. Last year’s quarterly dividend was 14p. The company continues to forecast a full-year payout of 60p a share, which is based on its policy of a 40-60% payout ratio through the investment cycle. Shares rose 40p to 1,713p, taking gains for this year to 16%, after first-quarter revenues of £7.36 billion topped City hopes by 4% and led to a 16% beat on the earnings per share result of 43.1p. The improvement was fuelled by strong sales of shingles vaccine Shingrix, which rose 18% to £945 million on the back of immunisation programmes in Australia and Europe, including the UK. It also benefited from earlier than anticipated supply to GSK’s partner in China. Markets outside the US now represent more than 50% of global Shingrix sales, up from 40% the same quarter a year ago. The vaccine has been launched in 39 countries, the majority of which have average cumulative immunisation rates below 5%. US sales decreased 7% against tougher comparatives, after the country’s immunisation rate at the end of 2023 reached 37% of the more than 120 million US adults currently recommended to receive Shingrix, up seven percentage points since the end of 2022. Arexvy, a respiratory syncytial virus vaccine for older adults, recorded sales of £182 million following its launch in the US in the third quarter of last year. More than seven million of the country’s 83 million adults at risk have so far been protected by Arexvy. In speciality medicines, strong performances in HIV, respiratory and immunology and oncology helped the division’s sales up by 17% to £2.5 billion. Total group sales rose 10% on a constant currency basis, with growth across the first half set to be stronger than the second due to tougher comparisons and the timing of Shingrix sales in China. GSK’s forecasts for 2024 now point to turnover growth towards the upper part of the 5-7% range and core operating profit growth of 9% to 11% compared with 7-10% previously. Core earnings per share growth of 8% to 10% is up from 6-9% given at 2023 results. The drugs pipeline now features 72 vaccines and specialty medicines, with 18 assets in the Phase III later stages of development. Chief executive Emma Walmsley said: “We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data readouts for four phase III medicines.” Taken together with other R&D achievements, she said GSK had strengthened its position in its key therapeutic areas of infectious diseases, HIV, respiratory/immunolo She added: “We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024.”Shares are now within 100p of where they were two years ago prior to the disclosure of US litigation on heartburn drug Zantac. They were just 1,316p in July last year. Jefferies is backing shares to reach 1,950p. It said today: “We are well above consensus 2026 estimates and believe long-acting HIV injectables, vaccines, and new pipeline launches mean profits likely face a blip not cliff on 2028 HIV patent expiries. “We argue given this under-appreciated growth profile, the shares offer attractive risk-reward ahead of potential Zantac class action settlement.” The Zantac issue has overshadowed the company’s attempts to convince the City of its standalone potential since splitting off consumer healthcare operation Haleo It continues to defend itself against the claims but doing so has taken time, with cases scheduled in Illinois, Texas and Nevada between now and March 2025. GSK reached a confidential settlement on a trial due to begin last month in California, a move it said reflected the company’s desire to avoid the distraction related to protracted litigation. It did not admit any liability in the settlement and said it would “continue to vigorously defend itself based on the facts and the science in all other Zantac cases”. |
Posted at 01/5/2024 10:23 by anhar Not bad figures generally and the modest net borrowing reduction is welcome as they have long been drowning in debt, but as an income investor I'm still feeling the effect of the large cut since the old GSK 80p payout in 21, the last full pre-demerger year. The intended 60p divi for 24, plus whatever the payout is from my HLN allocation for this year, is very likely to remain well below that 80p.But at least things are very slowly moving in the right direction. I've held GSK, and latterly GSK+HLN, since forever. I'm showing a gain but not much on an annualised basis, despite recent price rises. However price fluctuations are of very little interest really, it's all about the divis for me. The prospective 60p divi makes a forward yield of 3.5% at 1,700p, marginally below the FTSE100 and not very high for a share with their questionable record, but my strategy is to hold indefinitely in most cases. |
Posted at 03/4/2024 19:31 by motorhead75 My musings..I think the price isn’t going to move a great deal and will bounce around between £16.50-17.20 range up until the Zantac result in June/July. If we get a positive result, I can see £18.50+ quite quickly- remember the 14% jump after the federal court case result?! If it’s not in our favour, maybe a £1.50 drop, but regained steadily and will continue to climb.. I do think potential payouts are factored in to the current share price. It’ll be nice to see this share being given a fair valuation finally- the whole Zantac litigation reaction has baffled me. I work for GSK and have held shares for thirty years.. hopefully this time next year Rodney, we’ll all be millionaires! |
Posted at 03/4/2024 08:21 by geckotheglorious GSK picking up momentum, says HL’s ClaytonGSK (GSK) is ‘fighting back into contention’ with a bumper crop of new product launches in the pipeline, says Hargreaves Lansdown manager Steve Clayton. Clayton holds the Citywire Elite Companies AAA-rated pharmaceutical giant in his HL Select UK Income Shares fund, where it makes up 3% of the £138m portfolio. The group has been focused on restructuring, with a spin out of its consumer division Haleon (HLN), and developing new medicines such as shingles vaccine Shingrix, which Clayton said is ‘already a multi-billion dollars a year product’. The arrival of US activist investors Elliott Management a few years ago highlighted ‘the weak returns GSK had achieved, despite some real clinical strengths within the business’. ‘The company is now more optimistic about its research pipeline delivering more meaningful new drugs than for many years,’ Clayton said. ‘GSK’s business has more clarity about it these days and its current pipeline of 71 assets is predicted by GSK to contain at least 12 major new products to be launched from 2025 onwards.’ The shares dropped 2.5% to £16.65 on Tuesday, but have added almost 16% over the last 12 months. |
Posted at 07/2/2024 21:09 by pj84 From yesterdays questor column"GSK is performing well despite the legal clouds that hang over it Questor share tip: more of its vaccines are proving their worth and the company’s valuation fails to reflect punchy growth forecasts Russ Mould 6 February 2024 • 6:00am Strong full-year numbers last week, a planned dividend rise in 2024 and upgraded medium-term growth and profit forecasts all support our confidence in GSK, where a blossoming drugs pipeline gives additional visibility and increases the chances of some reward for readers in the form of both capital appreciation and income. A fourth dismissal or settlement of lawsuits relating to the heartburn treatment Zantac is also encouraging. While the legal cloud regarding the drug and its allegedly carcinogenic side-effects is far from fully lifted, the market’s worst fears regarding possible liabilities are yet to be borne out and the shares still trade some 9pc below highs reached almost two years ago. GSK still faces a lengthy list of cases, but the more that are settled, the greater the chance that investors can again focus on the day-to-day business, which is performing well. The launch of the respiratory syncytial virus vaccine Arexvy is going well, judging by 2023’s sales tally of £1.2bn, which is already 4pc of the group total. That nicely supplements the £3.4bn revenues from shingles vaccine Shingrix and helps the company to get over its embarrassing failure to match Pfizer, Moderna and AstraZeneca in the race to find a Covid vaccine. GSK now has 71 vaccines and speciality medicines in its drug development pipeline, including 18 at the Phase III stage, and is hoping for a dozen to come to market from 2025 onwards in areas such as HIV, oncology and respiratory conditions. This roadmap presumably underpins the upgrade to medium-term sales and profits growth targets offered by chief executive Dame Emma Walmsley alongside the full-year figures. GSK now expects compound annual growth rates of 7pc in revenues and 11pc in earnings between 2021 and 2026. Such a rate of progress would suggest that a multiple of barely 12 times forecast earnings looks decent value, especially when it is supported by a yield of 3.6pc, based on management’s guidance for a 60p-a-share dividend in 2024. GSK still looks like good value. Hold." |
Posted at 16/1/2024 13:58 by zho And some more from Shore's Sean Conroy:"Pre-trial hearings on the admissibility of expert testimony are scheduled on 22-25 Jan and should serve as an important indicator as to whether GSK is likely to make further settlements in 2024," Conroy said. However, he added: "As a reminder, the analogous Daubert hearings in the federal-level multi-district litigation ruled in favour of GSK (and other manufacturers) and resulted in the outright, robust dismissal of all MDL cases given the lack of credible scientific evidence." Conroy said that a worst-case scenario, in which Zantaz litigation costs GSK a total of $30.0bn, is currently being reflected in the share price. "[We] highlight any further clarity could support a material rerating of share; we have updated our sensitivity analysis and believe there remains a compelling risk-reward profile ahead of further updates on Zantac," he said. The broker has lifted its target price from 1,850.0p to 2,000.0p and kept a 'buy' rating. |
Posted at 11/1/2024 10:11 by anhar MHRANGOON is correct that you have to adjust for the consolidation in order to compare current values with the pre-demerger value. You can't just look at the share prices alone to make a comparison with the pre-demerger value, you need to consider the number of shares involved.The terms were that pre-demerger GSK holders received 1 HLN for every 1 GSK share held. Following that, GSK shares were consolidated at 4 for 5. So assume for example you held 1,000 old GSK, then you would now have 1,000 HLN and 800 current GSK. Using the above figures, the old GSK share price of 1,800p gives a value of £18,000 pre-dem. With new GSK now at 1,570p the holding is worth £12,560 and HLN £3,370, a total of £15,930 which is a loss of £2,070 or 11.5% on the old GSK value. Clearly then, the combined holding would have to rise to £18,000 just to break even, which could be satisfied by GSK or HLN alone or some combination of the two. |
Posted at 10/1/2024 18:17 by laurence llewelyn binliner The pre split share price in summer 2022 was about 1800, and with the share price today at 1570, plus the HLN share price of 337 gives us c1900 total, so we are ahead again at last 18 months later..GSK at 1800 stand alone would be great to see with HLN alongside adding value for those holders who kept them, as soon as they hit their debt to EBITDA ratio the dividend will pick up pace there too.. |
Posted at 15/11/2023 09:37 by abdullla GSK share price going against the rise in the Ftse,getting ready for the double drop tomorrow due to X-div |
Posted at 17/10/2023 14:40 by anhar Correct TM. GSK is an outstanding example of all those styles:Growth - after about a million years of holding, I'm up just 12.6% on original cost. This includes my HLN demerger shares. Not that I'm a growth player but that's the fact. Failed. Income - This is my style. Divis were static for eight years at 80p for old GSK from 2014-2021 though admittedly there was a 20p special back in 2016. Following that payout paralysis, after the demerger the combined divis from new GSK and HLN were slashed. Failed. Value - hard to see that GSK is underpriced with all that debt. Net debt at 30/6/23 was £18bn against net assets of £12bn and NAV is most certainly not above the share price. Failed. So indeed GSK has something to offer these three approaches and it's ultra reliable. It fails all three. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
